GRI Bio, Inc. participated in a Virtual Investor “What This Means” segment, discussing the 6-week interim biomarker data from its Phase 2a study in Idiopathic Pulmonary Fibrosis. The company is focused on developing therapies targeting Natural Killer T cells for inflammatory, fibrotic, and autoimmune diseases. GRI-0621, an inhibitor of iNKT cell activity, is being developed as a novel oral therapeutic for idiopathic pulmonary fibrosis, with additional dNKT agonists for systemic lupus erythematosus in the pipeline. GRI Bio aims to interrupt disease progression and restore immune system balance with over 500 proprietary compounds in development.

Read more at GlobeNewswire: GRI Bio CEO, Marc Hertz, Participates in Virtual Investor